Volume | 4,593,881 |
|
|||||
News | - | ||||||
Day High | 745.00 | Low High |
|||||
Day Low | 730.34 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eli Lilly and Co | LLY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
743.10 | 730.34 | 745.00 | 734.97 | 755.91 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
133,820 | 4,593,881 | $ 737.27 | $ 3,386,951,455 | - | 414.31 - 800.78 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:47 | 1 | $ 738.00 | USD |
Eli Lilly (LLY) Options Flow Summary
Eli Lilly and Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
698.34B | 950.16M | - | 34.12B | 5.24B | 5.52 | 133.26 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eli Lilly News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 724.00 | 795.4975 | 721.00 | 764.12 | 3,644,739 | 16.00 | 2.21% |
1 Month | 767.23 | 795.4975 | 718.30 | 753.49 | 2,603,849 | -27.23 | -3.55% |
3 Months | 736.85 | 800.78 | 718.30 | 761.24 | 2,857,373 | 3.15 | 0.43% |
6 Months | 581.16 | 800.78 | 561.65 | 679.73 | 3,096,949 | 158.84 | 27.33% |
1 Year | 416.01 | 800.78 | 414.31 | 594.68 | 3,032,601 | 323.99 | 77.88% |
3 Years | 182.99 | 800.78 | 182.92 | 392.58 | 2,990,090 | 557.01 | 304.39% |
5 Years | 118.44 | 800.78 | 101.36 | 278.02 | 3,328,239 | 621.56 | 524.79% |
Eli Lilly Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. |